Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma

Although recent advances have substantially improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 molecules genetically fused to type I interferons (IFN) synergize with the approved therapeutic bortezomib in arresting the proliferation of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:MAbs
Egile Nagusiak: Vasuthasawat, Alex, Yoo, Esther M., Trinh, Kham R., Lichtenstein, Alan, Timmerman, John M., Morrison, Sherie L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2016
Gaiak:
Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058616/
https://ncbi.nlm.nih.gov/pubmed/27362935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1207030
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak